Arrowhead Pharmaceuticals (ARWR) Current Leases (2011 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Current Leases came in at $7.8 million in Q1 2026, up 14.63% YoY from $6.8 million in Q1 2025, and up 3.25% on a QoQ basis from $7.5 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Current Leases (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 14 years of Current Leases data on file, last reported at $7.8 million in Q1 2026.
- Quarterly Current Leases rose 14.63% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 14.63% YoY) and the FY2025 annual result came in at $7.3 million, up 14.93% from the prior year.
- Current Leases advanced to $7.8 million in Q1 2026, from $7.5 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $10.6 million in Q3 2023 to a low of $2.7 million in Q4 2022.
- A 5-year average of $5.4 million and a median of $6.1 million in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases soared 280.51% — and 2024, when it slumped 39.96%.
- Tracing ARWR's Current Leases over 5 years: stood at $2.7 million in 2022, then climbed by 28.42% to $3.4 million in 2023, then soared by 91.76% to $6.6 million in 2024, then advanced by 14.77% to $7.5 million in 2025, then advanced by 3.25% to $7.8 million in 2026.
- The last three Current Leases figures came in at $7.8 million (Q1 2026), $7.5 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 5.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.32 Mn |
| Mar 31, 2026 | 7.77 Mn |
| Dec 31, 2025 | 7.53 Mn |
| Sep 30, 2025 | 7.29 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Mar 31, 2025 | 6.78 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Sep 30, 2024 | 6.34 Mn |
| Jun 30, 2024 | 6.05 Mn |
| Mar 31, 2024 | 5.29 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 10.56 Mn |
| Jun 30, 2023 | 2.82 Mn |
| Mar 31, 2023 | 2.71 Mn |
| Dec 31, 2022 | 2.66 Mn |
| Sep 30, 2022 | 2.78 Mn |
| Jun 30, 2022 | 2.88 Mn |
| Mar 31, 2022 | 2.91 Mn |
| Dec 31, 2021 | 2.83 Mn |
| Sep 30, 2021 | 2.25 Mn |